tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2021 Apr 23;1-27.
doi: 10.1080/22221751.2021.1921621. Online ahead of print.
A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters
Bao-Zhong Zhang[SUP] 1 [/SUP], Xiaolei Wang[SUP] 2 [/SUP], Shuofeng Yuan[SUP] 3 4 [/SUP], Wenjun Li[SUP] 1 [/SUP], Ying Dou[SUP] 2 [/SUP], Vincent Kwok-Man Poon[SUP] 4 [/SUP], Chris Chung-Sing Chan[SUP] 4 [/SUP], Jian-Piao Cai[SUP] 4 [/SUP], Kenn KaHeng Chik[SUP] 4 [/SUP], Kaiming Tang[SUP] 4 [/SUP], Chris Chun-Yiu Chan[SUP] 4 [/SUP], Ye-Fan Hu[SUP] 2 [/SUP], Jing-Chu Hu[SUP] 1 [/SUP], Smaranda Ruxandra Badea[SUP] 2 [/SUP], Hua-Rui Gong[SUP] 2 [/SUP], Xuansheng Lin[SUP] 2 [/SUP], Hin Chu[SUP] 3 4 [/SUP], Xuechen Li[SUP] 5 [/SUP], Kelvin Kai-Wang To[SUP] 3 4 [/SUP], Li Liu[SUP] 3 4 6 [/SUP], Zhiwei Chen[SUP] 3 4 6 [/SUP], Ivan Fan-Ngai Hung[SUP] 7 [/SUP], Kwok Yung Yuen[SUP] 3 4 [/SUP], Jasper Fuk-Woo Chan[SUP] 3 4 [/SUP], Jian-Dong Huang[SUP] 1 2 [/SUP]
Affiliations
Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and in vivo protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.
Keywords: COVID-19; SARS-CoV-2; Vaccine; linker-immunodominant site.
. 2021 Apr 23;1-27.
doi: 10.1080/22221751.2021.1921621. Online ahead of print.
A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters
Bao-Zhong Zhang[SUP] 1 [/SUP], Xiaolei Wang[SUP] 2 [/SUP], Shuofeng Yuan[SUP] 3 4 [/SUP], Wenjun Li[SUP] 1 [/SUP], Ying Dou[SUP] 2 [/SUP], Vincent Kwok-Man Poon[SUP] 4 [/SUP], Chris Chung-Sing Chan[SUP] 4 [/SUP], Jian-Piao Cai[SUP] 4 [/SUP], Kenn KaHeng Chik[SUP] 4 [/SUP], Kaiming Tang[SUP] 4 [/SUP], Chris Chun-Yiu Chan[SUP] 4 [/SUP], Ye-Fan Hu[SUP] 2 [/SUP], Jing-Chu Hu[SUP] 1 [/SUP], Smaranda Ruxandra Badea[SUP] 2 [/SUP], Hua-Rui Gong[SUP] 2 [/SUP], Xuansheng Lin[SUP] 2 [/SUP], Hin Chu[SUP] 3 4 [/SUP], Xuechen Li[SUP] 5 [/SUP], Kelvin Kai-Wang To[SUP] 3 4 [/SUP], Li Liu[SUP] 3 4 6 [/SUP], Zhiwei Chen[SUP] 3 4 6 [/SUP], Ivan Fan-Ngai Hung[SUP] 7 [/SUP], Kwok Yung Yuen[SUP] 3 4 [/SUP], Jasper Fuk-Woo Chan[SUP] 3 4 [/SUP], Jian-Dong Huang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33890550
- DOI: 10.1080/22221751.2021.1921621
Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and in vivo protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.
Keywords: COVID-19; SARS-CoV-2; Vaccine; linker-immunodominant site.